MeMed Wins FDA Breakthrough Status for AI-Driven Capillary Blood Infection Test

New updates have been reported about MeMed.

MeMed has secured U.S. FDA Breakthrough Device Designation for MeMed BV Flex, an AI-enabled host-response test that differentiates bacterial from viral infections using just a few drops of capillary blood. The assay, which runs on the MeMed Key platform and delivers a result in about 15 minutes, is designed for use not only in hospitals but also in CLIA-waived and other decentralized care environments, significantly broadening its potential commercial footprint.

The Breakthrough designation gives MeMed prioritized, more interactive FDA engagement and a faster regulatory pathway, while also enabling eligibility for Medicare’s NTAP and TCET programs that can support earlier and broader reimbursement, strengthening U.S. market access. Management sees the decision as validation of MeMed’s core machine-learning and multiplex host-protein technology, which is already behind the FDA-cleared MeMed BV test and the Breakthrough-designated MeMed Severity sepsis-risk tool, and believes the platform can extend into neurology, cardiology, autoimmunity, and other immune-mediated conditions, creating additional optionality beyond infectious disease once regulatory clearances and coverage are in place.